Mounjaro vs Ozempic: The Mechanism Difference That Explains Why One Works Better for Weight Loss

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Mounjaro (tirzepatide) activates both GLP-1 and GIP receptors, while Ozempic (semaglutide) activates only GLP-1, resulting in 5.5 pounds more weight loss on average in head-to-head trials
• Mounjaro shows superior A1C reduction (2.4% vs 1.9% at maximum doses) but higher rates of nausea and vomiting during titration
• Ozempic has longer real-world safety data (approved 2017 vs 2022) and lower discontinuation rates due to gastrointestinal side effects
• The GIP receptor activation in Mounjaro may improve insulin sensitivity and fat metabolism beyond what GLP-1 alone achieves, explaining the weight-loss advantage

Direct answer (40-60 words)

Mounjaro (tirzepatide) is a dual GLP-1 and GIP receptor agonist, while Ozempic (semaglutide) activates only GLP-1 receptors. In the SURPASS-2 head-to-head trial, Mounjaro produced 12.4% weight loss vs 6.7% for Ozempic at 40 weeks. Both slow gastric emptying and reduce appetite, but Mounjaro's GIP component adds metabolic effects that enhance weight loss and glucose control.

Table of contents

1. The mechanism difference that matters
2. Head-to-head trial results: SURPASS-2
3. Weight loss comparison across all doses
4. Diabetes control: A1C reduction data
5. Side effect profiles: where they differ
6. Dosing schedules and titration protocols
7. Cost comparison: brand vs compounded versions
8. The GIP receptor question: why it changes outcomes
9. What most articles get wrong about "dual agonist"
10. The decision framework: which medication for which patient
11. When to switch from one to the other
12. FAQ
13. Sources

The mechanism difference that matters

Both medications belong to the GLP-1 receptor agonist class, but the similarity ends there. The receptor targets explain everything about how they differ in practice.

Ozempic (semaglutide) is a selective GLP-1 receptor agonist. It binds to GLP-1 receptors in the pancreas, brain, stomach, and other tissues. When activated, these receptors:

• Increase insulin secretion in response to food
• Suppress glucagon (which raises blood sugar)
• Slow gastric emptying
• Reduce appetite through hypothalamic signaling
• Create a sense of fullness that lasts 5 to 7 days per injection

Mounjaro (tirzepatide) is a dual GLP-1 and GIP receptor agonist. It activates both GLP-1 receptors (same as semaglutide) and glucose-dependent insulinotropic polypeptide (GIP) receptors. The GIP component adds:

• Enhanced insulin secretion beyond GLP-1 alone
• Improved insulin sensitivity in muscle and liver tissue
• Altered fat metabolism and storage patterns
• Potential reduction in inflammation markers
• Possible effects on energy expenditure (still being studied)

The GIP receptor was historically thought to promote weight gain, which made tirzepatide's design controversial. Early GIP receptor agonists in animal models increased fat storage. The breakthrough insight was that dual activation of GLP-1 and GIP together produces synergistic effects that neither achieves alone. The mechanism is still being mapped, but the clinical results are unambiguous.

Head-to-head trial results: SURPASS-2

The SURPASS-2 trial (Frías et al., New England Journal of Medicine, 2021) is the only published head-to-head comparison of tirzepatide and semaglutide. The trial enrolled 1,879 adults with type 2 diabetes and compared three doses of tirzepatide (5 mg, 10 mg, 15 mg) against semaglutide 1 mg over 40 weeks.

Outcome	Tirzepatide 5 mg	Tirzepatide 10 mg	Tirzepatide 15 mg	Semaglutide 1 mg
Mean weight loss	7.6 kg (16.8 lbs)	9.3 kg (20.5 lbs)	11.2 kg (24.7 lbs)	5.7 kg (12.6 lbs)
% body weight lost	7.9%	9.5%	11.2%	5.9%
A1C reduction	2.01%	2.24%	2.30%	1.86%
Patients reaching A1C <7%	79%	83%	86%	79%
Nausea rate	17%	19%	22%	18%
Discontinuation due to adverse events	4.3%	7.1%	6.2%	3.7%

The weight-loss difference between tirzepatide 15 mg and semaglutide 1 mg was 5.5 kg (12.1 pounds) at 40 weeks. The difference is statistically significant (p < 0.001) and clinically meaningful by any standard.

The trial used semaglutide 1 mg, not the 2.4 mg dose approved for weight loss (Wegovy). No head-to-head trial comparing tirzepatide to semaglutide 2.4 mg has been published. Indirect comparisons across trials suggest tirzepatide still produces 3 to 4 kg more weight loss than semaglutide 2.4 mg, but direct evidence is lacking.

Weight loss comparison across all doses

Comparing the registration trials for obesity (not diabetes):

Trial	Drug	Dose	Duration	Mean weight loss	% body weight lost
SURMOUNT-1	Tirzepatide	5 mg	72 weeks	16.1 kg (35.5 lbs)	15.0%
SURMOUNT-1	Tirzepatide	10 mg	72 weeks	21.1 kg (46.5 lbs)	19.5%
SURMOUNT-1	Tirzepatide	15 mg	72 weeks	22.5 kg (49.6 lbs)	20.9%
STEP 1	Semaglutide	2.4 mg	68 weeks	14.9 kg (32.8 lbs)	14.9%
STEP 1	Placebo	N/A	68 weeks	2.4 kg (5.3 lbs)	2.4%

At the highest approved doses, tirzepatide 15 mg produces roughly 7.6 kg (16.8 pounds) more weight loss than semaglutide 2.4 mg over a similar timeframe. The difference is consistent across subgroups (age, sex, baseline BMI, diabetes status).

The dose-response curve for tirzepatide is steeper than for semaglutide. Moving from 5 mg to 15 mg tirzepatide adds 6.4 kg of weight loss. Moving from 1 mg to 2.4 mg semaglutide adds roughly 5 kg based on cross-trial comparisons.

For patients who plateau on semaglutide 2.4 mg, switching to tirzepatide often restarts weight loss. The pattern we see in FormBlends refill data: patients who lose 12% to 15% on semaglutide and stall often lose an additional 5% to 8% after switching to tirzepatide 10 to 15 mg over the next 6 months. This is pattern recognition, not a controlled study, but the consistency is notable.

Diabetes control: A1C reduction data

Both medications are FDA-approved for type 2 diabetes. The A1C reductions are among the largest ever seen for non-insulin medications.

Trial	Drug	Dose	Baseline A1C	A1C reduction	% reaching A1C <7%
SURPASS-1	Tirzepatide	5 mg	7.9%	1.87%	87%
SURPASS-1	Tirzepatide	10 mg	7.9%	1.89%	92%
SURPASS-1	Tirzepatide	15 mg	7.9%	2.07%	94%
SUSTAIN-1	Semaglutide	0.5 mg	8.1%	1.45%	72%
SUSTAIN-1	Semaglutide	1 mg	8.1%	1.53%	74%
PIONEER-1	Oral semaglutide	14 mg	8.0%	1.4%	69%

Tirzepatide's advantage in A1C reduction is smaller than its advantage in weight loss but still consistent. The difference is 0.3% to 0.5% depending on dose comparison, which translates to meaningful differences in long-term complication risk.

For patients with baseline A1C above 9%, tirzepatide is more likely to achieve target A1C without adding basal insulin. In the SURPASS-5 trial (patients with A1C 8.3% at baseline already on insulin glargine), tirzepatide 15 mg reduced A1C by 2.4% vs 1.4% for placebo, allowing many patients to reduce or stop insulin.

Side effect profiles: where they differ

The side effect profiles are similar but not identical. Both cause nausea, vomiting, diarrhea, and constipation during titration. The rates differ.

Side effect	Tirzepatide 15 mg (SURMOUNT-1)	Semaglutide 2.4 mg (STEP 1)
Nausea	29%	44%
Diarrhea	23%	30%
Vomiting	10%	24%
Constipation	17%	24%
Abdominal pain	9%	10%
Discontinuation due to GI side effects	4.3%	4.5%

The table shows semaglutide has higher rates of nausea and vomiting in the obesity trials. This contradicts the common belief that tirzepatide is "harder to tolerate." The confusion comes from comparing tirzepatide diabetes trials (which report higher nausea rates) to semaglutide obesity trials (different populations, different baseline characteristics).

When comparing obesity trials directly, semaglutide causes more nausea. When comparing diabetes trials directly (SURPASS-2), tirzepatide causes slightly more nausea. The difference is patient population, not the drug.

Serious adverse events:

• Pancreatitis: 0.2% for both medications across trials
• Gallbladder disease: 2.2% tirzepatide, 1.5% semaglutide (driven by rapid weight loss, not the drug directly)
• Hypoglycemia (in patients not on insulin or sulfonylureas): <1% for both
• Thyroid C-cell tumors: black box warning for both based on rodent data; no confirmed human cases causally linked to either drug

Both medications carry the same black box warning about thyroid C-cell tumors (medullary thyroid carcinoma) based on rodent studies. No human cases have been confirmed as caused by GLP-1 medications, but the warning remains. Both are contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Dosing schedules and titration protocols

Both are once-weekly subcutaneous injections. The titration schedules differ.

Ozempic (semaglutide) standard titration:

• Weeks 1-4: 0.25 mg once weekly
• Weeks 5-8: 0.5 mg once weekly
• Weeks 9+: 1 mg once weekly (maintenance for diabetes)
• Optional escalation to 2 mg for diabetes (not for weight loss)

Wegovy (semaglutide for obesity) standard titration:

• Weeks 1-4: 0.25 mg
• Weeks 5-8: 0.5 mg
• Weeks 9-12: 1 mg
• Weeks 13-16: 1.7 mg
• Weeks 17+: 2.4 mg (maintenance)

Mounjaro (tirzepatide) standard titration:

• Weeks 1-4: 2.5 mg once weekly
• Weeks 5-8: 5 mg once weekly
• Optional escalation every 4 weeks: 7.5 mg, 10 mg, 12.5 mg, 15 mg
• Most patients maintain on 10 mg or 15 mg

Tirzepatide's starting dose (2.5 mg) is pharmacologically active, not a tolerance-building dose like semaglutide's 0.25 mg. Patients often see weight loss in week 1 on tirzepatide, while semaglutide weight loss typically starts in weeks 5 to 8.

The faster titration means tirzepatide reaches maintenance dose in 8 to 20 weeks vs 16 to 20 weeks for semaglutide 2.4 mg. For patients who tolerate the medication well, this is an advantage. For patients sensitive to GI side effects, the faster escalation can be a disadvantage.

Injection technique: Both use prefilled pens. Injection sites are abdomen, thigh, or upper arm. Rotate sites weekly to prevent lipodystrophy. No significant difference in injection experience between the two.

Cost comparison: brand vs compounded versions

Brand-name pricing (as of April 2026, without insurance):

Medication	Dose	Monthly cost (list price)
Ozempic	0.5 mg or 1 mg	$968.52
Ozempic	2 mg	$968.52
Wegovy	2.4 mg	$1,349.02
Mounjaro	5 mg, 10 mg, or 15 mg	$1,069.08
Zepbound	5 mg, 10 mg, or 15 mg	$1,059.87

Insurance coverage varies widely. Many plans cover Ozempic and Mounjaro for diabetes but not Wegovy or Zepbound for weight loss. Prior authorization requirements are common. Copays range from $25 to $500+ per month depending on plan.

Compounded versions:

Compounded semaglutide and tirzepatide are available through licensed compounding pharmacies while the FDA shortage list includes these medications. Compounded versions are not FDA-approved and are not interchangeable with brand-name products.

Typical compounded pricing through FormBlends and similar platforms:

• Compounded semaglutide: $250 to $400 per month depending on dose
• Compounded tirzepatide: $400 to $550 per month depending on dose

Compounded tirzepatide costs more than compounded semaglutide because the raw material (tirzepatide peptide) is more expensive to synthesize. The dual receptor structure is more complex than semaglutide's single receptor target.

The cost difference between compounded versions is smaller than the clinical difference. For patients paying out of pocket, compounded tirzepatide offers better weight-loss outcomes per dollar spent, assuming tolerance is equal.

The GIP receptor question: why it changes outcomes

The GIP receptor's role in metabolism was misunderstood for decades. Early studies showed GIP increased fat storage in animal models, leading researchers to assume GIP receptor agonists would cause weight gain. Tirzepatide's success forced a rethinking of GIP biology.

Current understanding (Samms et al., Diabetes, 2020; Hammoud et al., Endocrine Reviews, 2021):

GIP receptor activation in the context of GLP-1 co-activation:

• Enhances insulin secretion synergistically with GLP-1
• Improves insulin sensitivity in adipose tissue, shifting fat storage from visceral to subcutaneous depots (subcutaneous fat is metabolically healthier)
• Reduces inflammation markers (IL-6, TNF-alpha) associated with obesity
• May increase energy expenditure through brown adipose tissue activation (still being studied in humans)
• Alters lipid metabolism, reducing triglycerides and increasing HDL cholesterol

Why GIP alone doesn't work but GIP + GLP-1 does:

The prevailing theory is that GLP-1 receptor activation creates a metabolic context in which GIP receptor activation becomes beneficial rather than harmful. GLP-1 slows gastric emptying and reduces appetite. In that slower-fed state, GIP's effects on insulin secretion and fat metabolism improve glucose disposal and fat oxidation rather than promoting storage.

This is an active research area. The full mechanism isn't settled, but the clinical outcomes are. Dual agonism produces better weight loss and glucose control than either receptor alone.

Diagram suggestion: Flowchart showing GIP receptor activation alone (leads to fat storage) vs GIP + GLP-1 together (leads to improved insulin sensitivity and fat oxidation), with key metabolic pathways labeled.

What most articles get wrong about "dual agonist"

The common error: describing tirzepatide as "twice as strong" or "more powerful" than semaglutide because it hits two receptors instead of one.

This is wrong. Receptor count doesn't equal potency. Tirzepatide is a different mechanism, not a stronger version of the same mechanism.

Semaglutide is actually a more potent GLP-1 receptor agonist than tirzepatide on a per-molecule basis. Semaglutide binds the GLP-1 receptor with higher affinity and longer duration than tirzepatide's GLP-1 component. If you measured pure GLP-1 receptor activation, semaglutide wins.

Tirzepatide's advantage comes from adding a second pathway (GIP), not from being better at the first pathway. The two receptors work synergistically, producing outcomes neither achieves alone.

The correct framing: tirzepatide is a broader mechanism, not a stronger one. It activates more pathways. That breadth translates to better weight loss and glucose control, but it's not a simple potency difference.

This matters because patients sometimes assume tirzepatide is "stronger semaglutide" and expect worse side effects. The side effect profiles are actually similar, and in obesity trials, semaglutide causes more nausea. The dual mechanism doesn't mean doubled side effects.

The decision framework: which medication for which patient

The clinical decision depends on goals, tolerance, cost, and medical history. Here's the framework we use when discussing options with patients.

Choose Mounjaro (tirzepatide) if:

• Primary goal is maximum weight loss
• Type 2 diabetes with A1C above 8% needing aggressive control
• Patient has plateaued on semaglutide and wants to restart progress
• Cost difference is acceptable (brand or compounded)
• No contraindications to GLP-1 medications

Choose Ozempic (semaglutide) if:

• Patient is sensitive to GI side effects and wants the gentlest titration
• Longer real-world safety data is a priority (semaglutide approved 2017 vs tirzepatide 2022)
• Type 2 diabetes with A1C 7% to 8% needing moderate control
• Cost is the primary concern (compounded semaglutide is cheaper)
• Patient has cardiovascular disease (semaglutide has cardiovascular outcome trial data; tirzepatide's cardiovascular trial results pending)

Consider switching from semaglutide to tirzepatide if:

• Weight loss has plateaued after 6+ months on semaglutide 2.4 mg
• A1C remains above 7% on maximum semaglutide dose
• Patient tolerates semaglutide well and wants more aggressive results
• Insurance or cost situation changes making tirzepatide accessible

Consider switching from tirzepatide to semaglutide if:

• GI side effects are intolerable despite dose reduction and dietary management
• Patient reaches goal weight and wants maintenance on a lower-cost option
• Cardiovascular disease develops and cardiologist prefers semaglutide's proven CV benefit

Don't switch back and forth frequently. Each medication takes 12 to 20 weeks to reach full effect. Switching every 2 to 3 months prevents either medication from working properly. Give each option at least 6 months before deciding it's not working.

When to switch from one to the other

The most common switch is semaglutide to tirzepatide after a plateau. The pattern: patient loses 10% to 15% body weight on semaglutide over 6 to 9 months, then weight loss stops despite continued medication and adherence.

The plateau question: Is this a true pharmacological plateau or a behavioral plateau?

A true pharmacological plateau means the medication's appetite suppression has weakened. You're eating the same amount you were when losing weight, but the scale stopped moving. This happens because your body adapts to lower weight by reducing metabolic rate and increasing hunger hormones (leptin resistance, ghrelin rebound).

A behavioral plateau means appetite suppression is still working, but you've gradually increased portion sizes or calorie-dense foods back to a level that matches your new lower metabolic rate. The medication is doing its job, but behavior has drifted.

The distinction matters because switching medications fixes pharmacological plateaus but not behavioral ones. If you're eating 2,500 calories per day on semaglutide and not losing weight, switching to tirzepatide while still eating 2,500 calories won't help.

How to tell the difference:

Track food intake carefully for 2 weeks. If calories have crept up from where they were during active weight loss, the plateau is behavioral. Address the behavior first (work with a dietitian, restart food logging, identify trigger foods). If calories are stable and appetite suppression feels weaker, the plateau is pharmacological. Switching medications is reasonable.

The switch protocol:

1. Finish your current semaglutide injection
2. Wait 7 days
3. Start tirzepatide at 2.5 mg (the standard starting dose, even if you were on high-dose semaglutide)
4. Titrate tirzepatide every 4 weeks per the standard schedule

Don't skip the starting dose. The GIP receptor component is new to your system. Starting at 10 mg tirzepatide because you were on 2.4 mg semaglutide causes severe nausea in most patients.

Expect a 2 to 4 week "adjustment window" where appetite suppression feels different. Tirzepatide's appetite suppression is described as more physical (stomach fullness) while semaglutide's is more cognitive (reduced food thoughts). Both work, but the subjective experience differs.

Weight loss typically restarts within 4 to 8 weeks of switching. Patients who plateau at 15% loss on semaglutide often lose an additional 5% to 10% on tirzepatide over the next 6 to 12 months.

The cardiovascular outcomes question

Semaglutide has proven cardiovascular benefit. The SELECT trial (Lincoff et al., New England Journal of Medicine, 2023) showed semaglutide 2.4 mg reduced major adverse cardiovascular events (heart attack, stroke, cardiovascular death) by 20% in patients with established cardiovascular disease and obesity.

Tirzepatide's cardiovascular outcomes trial (SURPASS-CVOT) is ongoing. Results are expected in late 2026. Until then, tirzepatide's cardiovascular effects are unknown.

For patients with established cardiovascular disease (prior heart attack, stroke, peripheral artery disease, or coronary artery disease), semaglutide is the safer choice based on current evidence. The proven 20% risk reduction is meaningful.

For patients without cardiovascular disease, the choice depends on weight-loss goals and tolerance. Tirzepatide's superior weight loss may translate to cardiovascular benefit (obesity itself is a cardiovascular risk factor), but we don't have trial data yet.

The conservative approach: if you have cardiovascular disease, start with semaglutide. If you don't have cardiovascular disease and want maximum weight loss, tirzepatide is reasonable.

FAQ

What is the main difference between Mounjaro and Ozempic? Mounjaro (tirzepatide) activates both GLP-1 and GIP receptors, while Ozempic (semaglutide) activates only GLP-1 receptors. The dual mechanism in Mounjaro produces greater weight loss (average 5.5 pounds more in head-to-head trials) and slightly better A1C reduction. Both are once-weekly injections with similar side effect profiles.

Which is better for weight loss, Mounjaro or Ozempic? Mounjaro produces more weight loss. In the SURPASS-2 trial, Mounjaro 15 mg resulted in 11.2% body weight loss vs 5.9% for Ozempic 1 mg over 40 weeks. Comparing obesity trials, Mounjaro 15 mg produces roughly 21% weight loss vs 15% for Ozempic 2.4 mg over 72 weeks. The difference is consistent across patient populations.

Which is better for diabetes, Mounjaro or Ozempic? Mounjaro produces slightly better A1C reduction. In head-to-head comparison, Mounjaro 15 mg reduced A1C by 2.3% vs 1.9% for Ozempic 1 mg. Both are highly effective for type 2 diabetes. The choice often depends on whether weight loss is also a goal (favoring Mounjaro) or cost and insurance coverage.

Does Mounjaro have worse side effects than Ozempic? No. The side effect profiles are similar. In obesity trials, Ozempic actually causes more nausea (44% vs 29%) and vomiting (24% vs 10%) than Mounjaro. Discontinuation rates due to side effects are nearly identical (4.3% vs 4.5%). The belief that Mounjaro is harder to tolerate comes from comparing different trial populations, not the medications themselves.

Can I switch from Ozempic to Mounjaro? Yes. The standard protocol is to finish your current Ozempic injection, wait 7 days, then start Mounjaro at the 2.5 mg starting dose. Titrate every 4 weeks per the standard schedule. Don't start at a high dose even if you were on high-dose Ozempic. Most patients who plateau on Ozempic restart weight loss within 4 to 8 weeks of switching to Mounjaro.

Which costs more, Mounjaro or Ozempic? Brand-name Mounjaro costs $1,069 per month vs $969 for Ozempic (diabetes dosing) or $1,349 for Wegovy (weight-loss dosing). Compounded tirzepatide costs $400 to $550 per month vs $250 to $400 for compounded semaglutide. Insurance coverage varies widely. Many plans cover both for diabetes but not for weight loss.

How long does it take to see results with Mounjaro vs Ozempic? Mounjaro often produces visible weight loss in weeks 1 to 4 because the starting dose (2.5 mg) is pharmacologically active. Ozempic's starting dose (0.25 mg) is a tolerance-building dose, so weight loss typically starts in weeks 5 to 8. Both reach maximum effect after 12 to 20 weeks at maintenance dose.

Which has more research, Mounjaro or Ozempic? Ozempic has more published research because it was approved earlier (2017 vs 2022). Semaglutide has cardiovascular outcome trial data showing 20% reduction in heart attacks and strokes. Tirzepatide's cardiovascular trial is ongoing with results expected in late 2026. For patients with heart disease, Ozempic's proven benefit makes it the safer choice currently.

Can I take Mounjaro and Ozempic together? No. Both medications work through overlapping mechanisms (GLP-1 receptor activation). Taking both together increases side effects without improving outcomes. If one medication isn't working, switching to the other is appropriate, but combining them is not recommended.

Do Mounjaro and Ozempic work the same way? Partially. Both activate GLP-1 receptors, which slows gastric emptying, increases insulin secretion, and reduces appetite. Mounjaro also activates GIP receptors, which enhances insulin sensitivity, alters fat metabolism, and may increase energy expenditure. The GIP component explains why Mounjaro produces more weight loss than Ozempic despite similar GLP-1 effects.

Which is safer long-term, Mounjaro or Ozempic? Both have similar safety profiles in published trials. Ozempic has longer real-world safety data (7 years vs 4 years on market). Both carry black box warnings about thyroid C-cell tumors based on rodent studies, though no human cases have been confirmed. Serious side effects (pancreatitis, gallbladder disease) occur at similar low rates for both medications.

Will insurance cover Mounjaro or Ozempic for weight loss? Coverage varies by plan. Most insurance covers Ozempic and Mounjaro for type 2 diabetes but not for weight loss alone. Wegovy (semaglutide for obesity) and Zepbound (tirzepatide for obesity) have better weight-loss coverage but still face frequent denials. Prior authorization is common. Compounded versions are not covered by insurance but cost less than brand-name out-of-pocket prices.

Sources

1. Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
3. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
4. Davies M et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). Lancet. 2021.
5. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
6. Samms RJ et al. How May GIP Enhance the Therapeutic Efficacy of GLP-1? Diabetes. 2020.
7. Hammoud R et al. Beyond the Pancreas: Contrasting Cardiometabolic Actions of GIP and GLP1. Endocrine Reviews. 2021.
8. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023.
9. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Molecular Metabolism. 2021.
10. Frias JP et al. Efficacy and safety of tirzepatide in patients with type 2 diabetes inadequately controlled with basal insulin (SURPASS-5). Diabetes Care. 2022.
11. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3). Lancet. 2021.
12. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016.
13. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity (STEP 4). JAMA. 2021.
14. American Diabetes Association. Standards of Medical Care in Diabetes - 2026. Diabetes Care. 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company or Novo Nordisk.